Piracetam: a review of pharmacological properties and clinical uses.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  CNS drug reviews

• Publication date

  2006-06-07

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1111/J.1527-3458.2005.TB00268.XPMID 16007238PMCID PMC6741724
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice

  2004cited by this paper
• Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment

  2004cited by this paper
• Piracetam for dementia or cognitive impairment.

  2004cited by this paper
• Facilitation of diazepam action by anticonvulsant agents against picrotoxin induced convulsions

  2004cited by this paper
• The fate of cognition in very old age: six-year longitudinal findings in the Berlin Aging Study (BASE).

  2003cited by this paper
• The Cholinergic Hypothesis of Age and Alzheimer's Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development

  2003cited by this paper
• Influence of the postlesion environment and chronic piracetam treatment on the organization of the somatotopic map in the rat primary somatosensory cortex after focal cortical injury.

  2003cited by this paper
• Piracetam inhibits the lipid-destabilising effect of the amyloid peptide Abeta C-terminal fragment.

  2003cited by this paper
• Piracetam Inhibits the Lipid-destabilising Effect of the Amyloid Peptide Ah C-terminal Fragment

  2002cited by this paper
• Piracetam for acute ischaemic stroke.

  2002cited by this paper
• Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs.

  2002cited by this paper
• Clinical Efficacy of Piracetam in Cognitive Impairment: A Meta-Analysis

  2002cited by this paper
• Glutamatergic neurotransmission in aging: a critical perspective.

  2001cited by this paper
• What Cognitive Changes can be Expected with Normal Ageing?

  2001cited by this paper
• Pyrrolidone derivatives.

  2001cited by this paper
• Multifaceted physiological response allows yeast to adapt to the loss of the signal recognition particle-dependent protein-targeting pathway.

  2001cited by this paper
• Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy.

  2001cited by this paper
• Decline across different domains of cognitive function in normal ageing: results of a longitudinal population‐based study using CAMCOG

  2000cited by this paper
• Piracetam in acute stroke: a systematic review

  2000cited by this paper
• Patterns of cognitive ageing

  2000cited by this paper
• Beneficial Effect of Piracetam Monotherapy on Post-Ischaemic Palatal Myoclonus

  1999cited by this paper
• Piracetam: Novelty in a Unique Mode of Action

  1999cited by this paper
• Piracetam reverses hippocampal membrane alterations in Alzheimer's disease

  1999cited by this paper
• Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo

  1998cited by this paper
• Piracetam in the Treatment of Acute Stroke

  1998cited by this paper
• Piracetam for the treatment of sickle cell disease in children- a double blind test.

  1998cited by this paper
• Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group.

  1997cited by this paper
• Treatment of Acute Ischemic Stroke With Piracetam

  1997cited by this paper
• Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain.

  1997influential reference
• Piracetam promotes mossy fiber synaptic reorganization in rats withdrawn from alcohol.

  1996cited by this paper
• Clinical Global Impressions in Alzheimer's Clinical Trials

  1996cited by this paper
• Piracetam in the treatment of myoclonus: an overview.

  1996cited by this paper
• Clinical trial of piracetam in patients with myoclonus: Nationwide multiinstitution study in Japan

  1996cited by this paper
• Piracetam in Patients with Chronic Vertigo

  1996cited by this paper
• Piracetam-induced changes to membrane physical properties. A combined approach by 31P nuclear magnetic resonance and conformational analysis.

  1995cited by this paper
• Piracetam impedes hippocampal neuronal loss during withdrawal after chronic alcohol intake.

  1995cited by this paper
• N-methyl-D-aspartate receptor density and membrane fluidity as possible determinants of the decline of passive avoidance performance in aging.

  1995cited by this paper
• Drug Therapy and Memory Training Programs: A Double-Blind Randomized Trial of General Practice Patients With Age-Associated Memory Impairment

  1994cited by this paper
• Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain.

  1993cited by this paper
• Long‐term and high‐dose piracetam treatment of Alzheimer's disease

  1993cited by this paper
• Platelet anti-aggregant and rheological properties of piracetam. A pharmacodynamic study in normal subjects.

  1993cited by this paper
• Treatment of Age-Related Cognitive Dysfunction: Pharmacological and Clinical Evaluation

  1993cited by this paper
• Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain.

  1993cited by this paper
• Effectiveness of piracetam in cortical myoclonus

  1993cited by this paper
• Moving from the Question of Efficacy to the Question of Therapeutic Relevance: An Exploratory Reanalysis of a Controlled Clinical Study of 130 Inpatients With Dementia Syndrome Taking Piracetam

  1992cited by this paper
• Neurotransmitters and Drugs. 3rd Edition. By Zygmunt L. Kruk and Christopher J. Pycock. London: Chapman & Hall. £11.95.

  1992cited by this paper
• Age-related deficits of central muscarinic cholinergic receptor function in the mouse: partial restoration by chronic piracetam treatment.

  1992cited by this paper
• The effects of piracetam on lipofuscin of the rat cerebellar and hippocampal neurons after long-term alcohol treatment and withdrawal: a quantitative study.

  1991cited by this paper
• Neurotransmitters and Drugs

  1991cited by this paper
• The treatment of severe action myoclonus.

  1989cited by this paper
• Piracetam in the treatment of different types of myoclonus.

  1988cited by this paper
• Prüfung der Wirkung von Piracetam (Nootrop*) auf die Wasserstoff-Clearance am Innenohr**

  1988cited by this paper
• [Assessment of the effect of piracetam (Nootrop) on hydrogen clearance in the inner ear].

  1988cited by this paper
• Beneficial effect of piracetam on renal blood flow in ischemically injured kidneys in the rat.

  1988cited by this paper
• [Nootropic drugs: effects and effectiveness. A reflection exemplified by a phase III study using piracetam].

  1987cited by this paper
• Nootropika: Wirkungen und Wirsamkeit. Eine Überlegung am Beispiel einer Phase III-Prüfung mit Piracetam

  1987cited by this paper
• Piracetam and Dyslexia: Effects on Reading Tests

  1987cited by this paper
• Synergistic effects of oxiracetam and piracetam in combination with antiepileptic drugs *

  1986cited by this paper
• Piracetam potentiates the antiepileptic action of carbamazepine in chronic experimental limbic epilepsy

  1986cited by this paper
• Effect of piracetam on cerebral blood flow and somatosensory evoked potential during normotension and hypotensive ischemia in cats.

  1985cited by this paper
• The Effects of Piracetam in Children with Dyslexia

  1985cited by this paper
• The spectrum of cortical myoclonus. From focal reflex jerks to spontaneous motor epilepsy.

  1985cited by this paper
• Piracetam attenuates the changes in the surface potential of the phosphatidylcholine monolayer produced by alcohols.

  1985cited by this paper
• Potentiation of the anticonvulsant effects of antiepileptic drugs by “nootropics”; a potential new therapeutic approach

  1984cited by this paper
• A Preliminary Report on Piracetam in Sickle Cell Anemia: A Double-Blind Crossover Clinical Trial and Effects on Erythrocyte Survival

  1983cited by this paper
• Diminished adherence of sickle erythrocytes to cultured vascular endothelium by piracetam

  1983influential reference
• Effects of membrane fluidity on secretion and receptor stimulation.

  1982cited by this paper
• Rapid communication the activating activity of vincamine, piracetam, and hydergine on the activity of the noradrenergic neurons of the locus coeruleus.

  1981cited by this paper
• Erythrocyte Deformability in Sickle‐Cell Crisis

  1981cited by this paper
• The activating action of vincamine, piracetam, and hydergine on the activity of the noradrenergic neurons of the locus coeruleus

  1981cited by this paper
• Piracetam diminishes hippocampal acetylcholine levels in rats.

  1981cited by this paper
• Prostacyclin-induced coronary vasodilation. Interactions with adenosine, cyclic AMP and energy charge in the rat heart in vitro.

  1980cited by this paper
• The efficacy of piracetam in vertigo. A double-blind study in patients with vertigo of central origin.

  1980cited by this paper
• Piracetam activity may differ according to the age of the recipient mouse.

  1980cited by this paper
• The efficacy of piracetam in vertigo. A double-blind study in patients with vertigo of central origin.

  1980cited by this paper
• Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity.

  1980cited by this paper
• [Quantitative evaluation of the efficacy of anti-arrhythmia agents in chronic ventricular arrhythmia].

  1979cited by this paper
• Neurotransmitters and Drugs

  1979cited by this paper
• Neurochemical Aspects of the Membrane Hypothesis of Aging

  1979cited by this paper
• Adhesion of normal and sickle erythrocytes to endothelial monolayer cultures.

  1979cited by this paper
• [Therapeutic effect of piracetam in a case of posthypoxic action myoclonus (author's transl)].

  1978cited by this paper
• Piracetam in the treatment of post-concussional syndrome. A double-blind study.

  1978cited by this paper
• [The effect of piracetam on global and regional cerebral blood flow in acute cerebral ischemia of man (author's transl)].

  1978cited by this paper
• Availability and plasma clearance of piracetam in man.

  1977cited by this paper
• Piracetam and acetamide in sickle-cell disease.

  1977cited by this paper
• Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.

  1977cited by this paper
• Availability and plasma clearance of piracetam in man.

  1977cited by this paper
• PIRACETAM AND ACETAMIDE IN SICKLE-CELL DISEASE

  1977cited by this paper
• Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium.

  1977cited by this paper
• Piracetam in sickle-cell anaemia.

  1976cited by this paper
• An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

  1976cited by this paper
• The Effect of Piracetam (Nootropil, UCB-6215) upon the Late Symptoms of Patients with Head Injuries

  1975cited by this paper
• Vers une pharmacologie de l'activité intégrative du cerveau. Tentative du concept nootrope en psychopharmacologie.

  1972cited by this paper
• [Genesis of a drug: Piracetam. Metabolism and biochemical research].

  1972cited by this paper
• [Pharmacology of integrative activity of the brain. Attempt at nootropic concept in psychopharmacology].

  1972cited by this paper

• Discovery and Characterization of Novel Spirotriazoloquinazolines as Potential Neuroprotectors: Synthesis, Computational Screening, and Preliminary In Vivo Evaluation

  2026cites this paper
• Cobalt-Catalyzed Alkene Alkylarylation: Access to Pyrrolidinones.

  2025cites this paper
• Elucidating the Three‐Dimensional Structure of Piracetam through Rotational Spectroscopy

  2025cites this paper
• Piracetam reverses scopolamine-induced memory disorder in mice: an animal model using behavioral, oxidative, and cholinesterase biomarkers.

  2025cites this paper
• Recent advances in direct asymmetric reaction of furanone

  2025cites this paper
• Recombinant Walnut-Derived Peptide Ameliorates d-Galactose-Induced Cognitive Deficits.

  2025cites this paper
• Effects of Choline-Rich Fermented Crescentia cujete on Blood Parameters, Superoxide Dismutase, and Cerebral Interleukin-6 in Rats after Induced Ischemic Stroke

  2025cites this paper
• Pioneering RP-HPLC strategy for synchronous evaluation of assay and dissolution testing of piracetam and vincamine: A promising combination for cognitive and cerebrovascular disorders

  2025cites this paper
• Drugs and Nutrients in Epilepsy: Vitamin B6 and the Ketogenic Diet

  2025cites this paper
• Positive AMPA and Kainate Receptor Modulators and Their Therapeutic Potential in CNS Diseases: A Comprehensive Review

  2025cites this paper
• EVALUATION OF PROTECTIVE EFFECT OF CURCUMIN AGAINST CYCLOPHOSPHAMIDEINDUCED COGNITIVE IMPAIRMENT IN SWISS ALBINO MICE

  2025cites this paper
• Expert Perspectives on the Clinical Use of Piracetam and Citicoline in Stroke and Piracetam Monotherapy in Treating Vertigo

  2025cites this paper
• Modulation of VEGF/eNOS/TGF‐β Axis by Piracetam as a New Avenue to Ameliorate Valproic Acid‐Induced Placental Toxicity and Teratogenicity in Rats

  2025cites this paper
• The mechanistic role of piracetam in the management of vascular dementia.

  2025cites this paper
• Targeting NMDA receptors in pain management: therapeutic innovations through piracetam repurposing.

  2025cites this paper
• Pharmacological Management of Mild Cognitive Impairment: From Symptomatic Treatment to Disease Modification—A Narrative Review

  2025cites this paper
• Analysis of drugs' use for the treatment of dementia in psychiatry

  2024cites this paper
• Piracetam as Neuroprotective, Anticonvulsant, and Anti-Anxiety Agent: An In Vivo Study on Ptz Epileptic Rats.

  2024cites this paper
• Current state of research in the field of intranasal dosage forms and the possibility of using piracetam as an intranasal gel

  2024cites this paper
• Pharmacological adjuncts and transcranial magnetic stimulation-induced synaptic plasticity: a systematic review

  2024cites this paper
• Thiophene-fused γ-lactams inhibit the SARS-CoV-2 main protease via reversible covalent acylation

  2024cites this paper
• Development of new nanofibrous nerve conduits by PCL-Chitosan-Hyaluronic acid containing Piracetam-Vitamin B12 for sciatic nerve: A rat model.

  2024cites this paper
• Physicochemical investigations of nootropic drug piracetam for enhanced solubilization as nano drug carrier under the influence of single and mixed micellar formulations: An optimized approach towards drug delivery

  2024cites this paper
• Trolox, Ferulic, Sinapic, and Cinnamic Acid Derivatives of Proline and GABA with Antioxidant and/or Anti-Inflammatory Properties

  2024cites this paper
• New triazole-based hybrids as neurotropic agents

  2024cites this paper
• Abnormal Astrocyte Heterogeneity in the Dentate Gyrus of Rats Prone to Audiogenic Seizures Can Be Corrected by the Nootropic Drug Piracetam

  2024cites this paper
• The Neuroprotective Effects of Nano-Scaffolds Enriched with Piracetam and Octreotide Drugs on Neural Cells Following Oxidative Stress

  2024cites this paper
• A new differential diagnosis of the skin rashes along the ventriculoperitoneal shunt: Do no harm to the patient

  2024cites this paper
• Fermented calabash fruit-derived choline (Crescentia cujete L.) against artificial-induced ischemic stroke in rat models: Analysis of N/LR, PWR, histopathology, GM-CSF, and VEGF

  2024cites this paper
• In vitro and in silico investigation of FDA‐approved drugs to be repurposed against Alzheimer's disease

  2024cites this paper
• Comparison of Effectiveness of Brivaracetam and Levetiracetam for Prophylaxis of Early Post-Traumatic Seizures: A Prospective Comparative Interventional Study

  2024cites this paper
• Piracetam mitigates nephrotoxicity induced by cisplatin via the AMPK-mediated PI3K/Akt and MAPK/JNK/ERK signaling pathways.

  2024cites this paper
• Presynaptic antiseizure medications - basic mechanisms and clues for their rational combinations

  2024cites this paper
• Epitranscriptomic regulation of cortical neurogenesis via Mettl8-dependent mitochondrial tRNA m3C modification.

  2023cites this paper
• Supplementary Pharmacotherapy for the Behavioral Abnormalities Caused by Stressors in Humans, Focused on Post-Traumatic Stress Disorder (PTSD)

  2023cites this paper
• Cure of Alzheimer’s Dementia Requires Addressing All of the Affected Brain Cell Types

  2023cites this paper
• Formulating treatment of major psychiatric disorders: algorithm targets the dominantly affected brain cell-types

  2023cites this paper
• Identification of some Novel Racetams as Potential Anti-Convulsant Agents: Virtual Screening, Molecular Docking, and ADMET Study

  2023cites this paper
• Response to Letter to the Editor from Finsterer: “Encephalitis Associated With SARS-CoV-2 Infection in a Child With Chiari Malformation Type I”

  2023cites this paper
• Sea cucumber peptides protect against memory impairment by regulating dopamine/serotonin metabolization and synapse plasticity of mice hippocampus

  2023cites this paper
• The Outcome of Antipsychotics-induced Tardive Syndromes: A Ten-year Follow-up Study

  2023cites this paper
• Therapeutic enhancing potential of piracetam with diethylstilbestrol in prevention of grand-mal seizures in rats: inhibition of PI3K/Akt/mTOR signaling pathway and IL-1β, IL-6, TNF-α cytokines levels.

  2023cites this paper
• Biological Activity of Hexaazaisowurtzitane Derivatives

  2023cites this paper
• The neuroprotective effects of Piracetam on cisplatin-induced cognitive decline

  2023cites this paper
• Exploring effects of Simvastatin on coagulation mediators to alleviate the advancement of high cholesterol diet triggered neurodegeneration

  2023cites this paper
• Thiofunctionalized γ-Lactams

  2023cites this paper
• EVALUATION OF THE EFFICIENCY OF THE NEUROPROTECTIVE DRUGS AFTER PRENATAL HYPOXIA

  2023cites this paper
• Synthesis, Characterization, Docking Studies and Antiepileptic Activity of Novel Piracetam Derivatives

  2023cites this paper
• Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves α7AChRs on interneurons in hippocampal slices from rat.

  2022cites this paper
• Piracetam-induced neuroprotection in lipopolysaccharides-challenged EOC-20 cells and mouse brain via attenuating oxidative stress

  2022cites this paper
• Pharmacological characterization of a novel putative nootropic beta-alanine derivative, MB-005, in adult zebrafish

  2022cites this paper
• Analysis of Two Mixtures Containing Racetams in Their Pharmaceuticals Using Simple Spectrophotometric Methodologies.

  2022cites this paper
• Benefits and Harms of ‘Smart Drugs’ (Nootropics) in Healthy Individuals

  2022cites this paper
• Combining Racetams with a Sweetener through Complexation

  2022cites this paper
• Crystal structures of cocrystals of 2,7-dihydroxynaphthalene with isoniazid and piracetam.

  2022cites this paper
• The issues of classification and characterization of neurotropic agents in the treatment of patients with cerebrovascular diseases

  2022cites this paper
• Piracetam as a Therapeutic Agent for Doxorubicin-Induced Cognitive Deficits by Enhancing Cholinergic Functions and Reducing Neuronal Inflammation, Apoptosis, and Oxidative Stress in Rats

  2022cites this paper
• Strategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update

  2022cites this paper
• Piracetam attenuates cyclophosphamide-induced hepatotoxicity in rats: Amelioration of necroptosis, pyroptosis and caspase-dependent apoptosis.

  2022cites this paper
• Mechanisms associated with the dysregulation of mitochondrial function due to lead exposure and possible implications on the development of Alzheimer’s disease

  2022cites this paper
• Melatonin improves cognitive impairment by suppressing endoplasmic reticulum stress and promoting synaptic plasticity during chronic cerebral hypoperfusion in rats.

  2022cites this paper
• Effect of roll compaction pressure on the properties of high drug-loaded piracetam granules and tablets

  2022cites this paper
• Hemolymph Metabolism Analysis of Honey Bee (Apis mellifera L.) Response to Different Bee Pollens

  2022cites this paper
• Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs

  2022cites this paper
• Comparison of the Effects of Citicoline and Piracetam on Hypoxic-ischemic Brain Damage in Neonatal Rabbits

  2022cites this paper
• A new green approach for the reduction of consumed solvents and simultaneous quality control analysis of several pharmaceuticals using a fast and economic RP-HPLC method; a case study for a mixture of piracetam, ketoprofen and omeprazole drugs

  2022cites this paper
• Citius, Altius, Fortius—Advanced Mass Spectrometry in Service of Forensic Analysis

  2022cites this paper
• Asymmetric addition and cycloaddition reactions with ylidene‐five‐membered heterocycles

  2021cites this paper
• The effect of piracetam on behavioral reactions of adult rats and morphological changes in the brain after whole body fractionated gamma irradiation: an exploratory study

  2021cites this paper
• Cocrystals, Coamorphous Phases and Coordination Complexes of γ‐ and ε‐Lactams

  2021cites this paper
• Nootropics (Piracetam, Pyritinol, Co-dergocrine, Meclophenoxat, Pentoxifylline, Nimodipine)

  2021cites this paper
• Synthesis of Functionalized Diethyl(pyrrolidin-2-yl)phosphonate and Diethyl(5-oxopyrrolidin-2-yl)phosphonate

  2021cites this paper
• HIV-1 Tat and cocaine impact astrocytic energy reservoir influence on miRNA epigenetic regulation.

  2021cites this paper
• Adjunctive Approaches to Aphasia Rehabilitation: A Review on Efficacy and Safety

  2021cites this paper
• A Review on Synthesis and Pharmacological Activities of Piracetam and its Derivatives

  2021cites this paper
• Psychostimulants and opioids differentially influence the epigenetic modification of histone acetyltransferase and histone deacetylase in astrocytes

  2021cites this paper
• Influence of psychostimulants and opioids on epigenetic modification of class III histone deacetylase (HDAC)-sirtuins in glial cells

  2021cites this paper
• Antidementiva

  2021cites this paper
• Cholinesterase inhibitors for the treatment of dementia: real-life data in Hungary

  2021cites this paper
• Pharmacological Approaches in the Augmentation and Recovery of Brain Function

  2021cites this paper
• A Novel Phenylpyrrolidine Derivative: Synthesis and Effect on Cognitive Functions in Rats with Experimental Ishemic Stroke

  2021cites this paper
• Synthesis, Characterization and Biological Activate 5-(Hydroxymethyl) Pyrrolidin-2-One at Room Temperature

  2021cites this paper
• Liver proteome alterations in psychologically distressed rats and a nootropic drug

  2021cites this paper
• Levetiracetam promoted rat embryonic neurogenesis via NMDA receptor-mediated mechanism in vitro.

  2021cites this paper
• Study of the cyclization of N-hydroxy- and N-methoxy-N-(2-oxoalkyl)amides

  2021cites this paper
• Study on the Regulation of Piracetam Crystallization Behavior

  2021cites this paper
• Pharmacokinetic Drug–Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients

  2021cites this paper
• Evaluasi Rasionalitas Penggunaan Obat Neuroprotektif pada Pasien Stroke Iskemik di Rumah Sakit Stroke Nasional Bukittinggi

  2021cites this paper
• Handbook of Pyrrolidone and Caprolactam Based Materials: Synthesis, Characterization and Industrial Applications, 6 Volume Set: Cocrystals, Coamorphous Phases and Coordination Complexes of Î3â•’ and <fc>Îμâ•’Lactams</fc>

  2021cites this paper
• Cerebral Vasospasm after Posterior Fossa Tumor Surgery: A Case Report and Literature Review

  2020cites this paper
• New Methods Used in Pharmacokinetics and Therapeutic Monitoring of the First and Newer Generations of Antiepileptic Drugs (AEDs)

  2020cites this paper
• Innovative Approaches to Aphasia Rehabilitation: a Review on Efficacy, Safety and Controversies

  2020cites this paper
• A case of Atypical Lance Adams Syndrome in respiratory failure following Organophosphate poisoning

  2020cites this paper
• The potential for one drug, administered at the earliest preclinical stage, to prevent the subsequent decline of cognition that eventuates in dementia

  2020cites this paper
• Efficient production of gamma‐aminobutyric acid by engineered Saccharomyces cerevisiae with glutamate decarboxylases from Streptomyces

  2020cites this paper
• Аналіз вітчизняного фармацевтичного ринку психостимулюючих та ноотропних засобів групи N06BX

  2020cites this paper
• Asymmetric vinylogous Michael addition of 5-substituted-furan-2(3H)-ones to an α,β-unsaturated-γ-lactam.

  2020cites this paper
• Theoretical justification of a purposeful search of potential neurotropic drugs

  2020cites this paper
• L-carnitine+piracetam for fatigue and muscular strength of patients with post-poliomyelitis

  2020cites this paper
• Aligning Acute and Chronic Functional Readouts and Utilizing Zolpidem to Improve Neurological Impairments After Cardiac Arrest by

  2020cites this paper